Berenberg resumed coverage on Halozyme Therapeutics with a new price target

3/27/23 7:25:58 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Berenberg resumed coverage of Halozyme Therapeutics with a rating of Buy and set a new price target of $58.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HALO

Date	Price Target	Rating	Analyst
5/14/2025	$62.00	Overweight → Equal-Weight	Morgan Stanley
5/13/2025	$47.00	Market Perform → Underperform	Leerink Partners
10/7/2024	$58.00 → $62.00	Overweight → Equal Weight	Wells Fargo
9/19/2024	$52.00 → $57.00	Overweight → Neutral	JP Morgan
6/7/2024	$48.00 → $51.00	Overweight → Neutral	Piper Sandler
2/29/2024	$54.00	Outperform	TD Cowen
7/24/2023	$61.00	Buy	H.C. Wainwright
7/24/2023	$43.00 → $45.00	Buy → Neutral	Goldman